March 23, 2023
Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
XBiotech: XBiotech begins patient enrolment in French National Cancer Institute sponsored phase I/II/III study for Natrunix therapy for colorectal cancer
XBiotech announced the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much
Read full article »
March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
March 23, 2023
Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer.
Read more